General Information of Drug (ID: DMV3L62)

Drug Name
Sym023 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMV3L62

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MBG453 DMBPY9Z Myelodysplastic syndrome 2A37 Phase 3 [3]
RO7121661 DM8A120 Esophageal squamous cell carcinoma 2E60.1 Phase 2 [4]
GSK4069889 DMV6SNU Non-small-cell lung cancer 2C25 Phase 2 [5]
AZD7789 DMOIHWI Hodgkin lymphoma 2B30 Phase 2 [6]
TB006 DMKN524 Alzheimer disease 8A20 Phase 2 [7]
BGB-A425 DMI42Q0 Non-small-cell lung cancer 2C25 Phase 1/2 [8]
LY3415244 DM5QO1A Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
LY3321367 DMD51GC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
INCAGN2390 DM5SO1T Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis A virus cellular receptor 2 (TIM3) TT1RWL7 HAVR2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03489343) Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Symphogen.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline.
6 Clinical pipeline report, company report or official report of AstraZeneca
7 Clinical pipeline report, company report or official report of TrueBinding
8 Clinical pipeline report, company report or official report of BeiGene.
9 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
10 Clinical pipeline report, company report or official report of Agenus.